Drug Update · Dermatology

Dupilumab Label Updates 2025: Atopic Dermatitis Indication and Dosing

August 14, 2026

Indication

Treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis [1]

Adult approved dose

Initial 600 mg, followed by 300 mg every 2 weeks (Q2W) [1]

Number of adult subjects (SOLO1/2/CHRONOS)

2,119 adult subjects enrolled across SOLO 1, SOLO 2, and CHRONOS [8]

SOLO 1 IGA 0 or 1 (Week 16)

38% with DUPIXENT versus 10% with placebo [8]

SOLO 2 IGA 0 or 1 (Week 16)

36% with DUPIXENT versus 9% with placebo [8]

CHRONOS IGA 0 or 1 (Week 16)

39% with DUPIXENT + TCS versus 12% with placebo + TCS; EASI-75 69% versus 23% [8]

Clinical Perspective

This affects dermatologists and other clinicians who treat adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis, as the label specifies the approved patient age range and disease severity for DUPIXENT use ^[1]. The source-confirmed trial results and prescribing information support use of DUPIXENT with or without topical corticosteroids and specify the approved adult dosing regimen beginning with a 600 mg initial dose followed by 300 mg every 2 weeks ^[1]^[3]. What comparative evidence from the provided sources should clinicians use when choosing between dupilumab and other AD therapies such as tralokinumab, lebrikizumab, or topical phosphodiesterase inhibitors like difamilast?

Dr. Divya Agarwal, MBBS, MD (Dermatology, Venereology & Leprosy) · Dermatology

The DUPIXENT (dupilumab) prescribing information was revised 06/2025 and continues to list an indication for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable ^[1]. The label specifies subcutaneous administration and the approved adult dosing of an initial 600 mg dose followed by 300 mg every 2 weeks; pivotal randomized controlled trials (SOLO 1, SOLO 2, CHRONOS) reported higher rates of IGA 0 or 1 responders with dupilumab versus placebo ^[1]^[3]. Clinicians should consult current prescribing information for full dosing guidance.

Clinical Context

DUPIXENT (dupilumab) is described in the product label as an interleukin-4 receptor alpha (IL-4Rα) antagonist that inhibits IL-4 and IL-13 signaling by binding to the IL-4Rα subunit shared by IL-4 and IL-13 receptor complexes; blocking IL-4Rα inhibits IL-4 and IL-13 cytokine-induced inflammatory responses ^[3]. The FDA prescribing information lists DUPIXENT as indicated for adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis and notes that it can be used with or without topical corticosteroids ^[1]^[2]^[3]. Information comparing dupilumab directly with tralokinumab, lebrikizumab, or difamilast was not reported in the provided source excerpts.

Key Findings

The SOLO 1 trial showed DUPIXENT achieved IGA 0 or 1 in 38% versus 10% with placebo at Week 16 in adult subjects with moderate-to-severe AD ^[3].
The SOLO 2 trial showed DUPIXENT achieved IGA 0 or 1 in 36% versus 9% with placebo at Week 16 in adult subjects with moderate-to-severe AD ^[3].
The CHRONOS trial (DUPIXENT with concomitant topical corticosteroids) showed DUPIXENT achieved IGA 0 or 1 in 39% versus 12% with placebo plus topical corticosteroids at Week 16 in adult subjects; CHRONOS also reported EASI-75 of 69% versus 23% at Week 16 for DUPIXENT plus topical corticosteroids versus placebo plus topical corticosteroids ^[3].

These randomized, double-blind, placebo-controlled trials formed the efficacy evidence presented in the label for atopic dermatitis ^[3].

Safety & Tolerability

Most common adverse reactions (atopic dermatitis cohort, incidence ≥1%) listed in the prescribing information include injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye, and eosinophilia ^[1].

Study Design

The label summarizes three randomized, double-blind, placebo-controlled trials (SOLO 1, SOLO 2, and CHRONOS) in adult subjects with moderate-to-severe atopic dermatitis; the three trials enrolled a total of 2,119 adult subjects ^[3]. The prespecified primary endpoint in these trials was the proportion of subjects achieving an Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) with at least a 2-point improvement from baseline to Week 16 ^[3]. SOLO 1 and SOLO 2 were monotherapy trials for 16 weeks, and CHRONOS evaluated DUPIXENT with concomitant topical corticosteroids for up to 52 weeks ^[3].

FAQ

What is DUPIXENT approved for?

DUPIXENT (dupilumab) is indicated for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The prescribing information states that DUPIXENT can be used with or without topical corticosteroids.

How does dupilumab work?

Dupilumab is a human monoclonal IgG4 antibody that specifically binds to the IL-4Rα subunit shared by the IL-4 and IL-13 receptor complexes, inhibiting IL-4 and IL-13 signaling through those receptors. Blocking IL-4Rα inhibits IL-4- and IL-13-induced inflammatory responses, including the release of proinflammatory cytokines and chemokines.

What is the recommended dose for atopic dermatitis in adults?

The label-recommended adult dosing for atopic dermatitis is an initial dose of 600 mg (two 300 mg injections), followed by 300 mg given every 2 weeks (Q2W). DUPIXENT is administered by subcutaneous injection, and the prescribing information includes detailed weight- and age-based dosing for pediatric patients. Clinicians should consult current prescribing information for full dosing guidance.

What are the most common side effects?

The prescribing information lists, among the most common adverse reactions in patients with atopic dermatitis, injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye, and eosinophilia. The label also includes warnings and precautions for hypersensitivity reactions and eye disorders.

Clinicians should consult current prescribing information for complete dosing guidance.

Dupilumab Label Updates 2025: Atopic Dermatitis Indication and Dosing

Direct Clinical Takeaway & Evidence Summary

Dupilumab Label Updates 2025: Atopic Dermatitis Indication and Dosing

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

Study Design

FAQ

References

Get weekly clinical updates for Dermatology in your inbox.

Related Clinical Updates

Deucravacitinib (SOTYKTU): Clinical Deep‑Dive in Plaque Psoriasis

FDA Approves difamilast for Mild‑Moderate AD: 38% IGA Success in Trial 2

FDA Approves difamilast for Mild‑Mod AD: 38% IGA Success (Trial 2)

Verified HCP Portal